Kimball Johnson - Investigator ...

Dr. Kimball Johnson, MD

Claim this profile

iResearch Atlanta

Studies Alzheimer's Disease
Studies Cognitive Impairment
23 reported clinical trials
24 drugs studied

Area of expertise

1

Alzheimer's Disease

Kimball Johnson, MD has run 10 trials for Alzheimer's Disease. Some of their research focus areas include:

Stage II
Stage III
Stage IV
2

Cognitive Impairment

Kimball Johnson, MD has run 4 trials for Cognitive Impairment.

Affiliated Hospitals

Image of trial facility.

IResearch Atlanta

Image of trial facility.

CenExel IResearch, LLC

Clinical Trials Kimball Johnson, MD is currently running

Image of trial facility.

LY4006895

for Alzheimer's Disease

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Part A and 61 weeks for Part B, including a screening period for each part.

Recruiting

0 awards

Phase 1

1 criteria

Image of trial facility.

KYN-5356

for Schizophrenia

This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) effects of 3 different dose regiments of KYN-5356 and placebo for 28 days. Participants will be randomized to one of 4 treatment groups: placebo, KYN-5356 low dose, KYN-5356 medium dose, KYN-5356 high dose. Participants will be admitted to the clinic on Day -3 and will remain in residence at the clinic for 32 days, from baseline through the treatment period. Participants will be administered investigational medicinal product on Days 1 through 28. Efficacy, safety, PK and exploratory PD assessments will be performed throughout the dosing period. Participants will be discharged on Day 29 after safety assessments are completed and return for a follow-up visit on Day 42. A subset of participants from selected sites will undergo electrophysiological assessments to evaluate the effect of KYN-5356 on neurophysiological measures of brain function.

Recruiting

0 awards

Phase 2

2 criteria

More about Kimball Johnson, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 5 Active Clinical Trials

Treatments Kimball Johnson, MD has experience with

  • Placebo
  • Serdexmethylphenidate (SDX) And Dexmethylphenidate (d-MPH)
  • Donanemab
  • Buntanetap
  • CYB004
  • Psychotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kimball Johnson, MD specialize in?

Is Kimball Johnson, MD currently recruiting for clinical trials?

Are there any treatments that Kimball Johnson, MD has studied deeply?

What is the best way to schedule an appointment with Kimball Johnson, MD?

What is the office address of Kimball Johnson, MD?

Is there any support for travel costs?